Gland Pharma's Eribulin Mesylate Injection Approved by FDA for Cancer Treatment

9 Apr 2024 , 12:48 PM

Gland Pharma made a significant announcement on Monday regarding the FDA approval of Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial. This drug, which is an anti-cancer medication, has been greenlit for treating breast cancer and liposarcoma, marking a crucial advancement in cancer treatment options. The approval from the United States Food and Drug Administration (USFDA) positions the product as the first generic approval on the market, representing a milestone achievement for Gland Pharma. The company intends to swiftly introduce the product into the market through its strategic marketing partner, leveraging its extensive reach and expertise.

According to IQVIA, a leading healthcare data analytics company, Eribulin Mesylate Injection has amassed significant sales figures in the United States, amounting to approximately $92 million over the twelve-month period ending in February 2024. This underscores the potential market demand and revenue prospects for Gland Pharma.

Collaborating closely with Orbicular Pharmaceutical Technologies Private Limited, Gland Pharma is actively engaged in the co-development of several complex injectables, including Eribulin Mesylate Injection. This partnership reflects Gland Pharma’s commitment to innovation and expanding its product portfolio to address critical medical needs.

Founded in Hyderabad, India in 1978, Gland Pharma has evolved into one of the largest and fastest-growing generic injectables manufacturing companies globally. With a presence in over 60 countries, including key markets like the United States, Europe, Canada, and Australia, Gland Pharma operates primarily under a business-to-business (B2B) model. Its remarkable growth trajectory is further supported by its robust capabilities in pharmaceutical research, development, manufacturing, and marketing of complex injectables.

Moreover, India’s pharmaceutical market demonstrated resilient growth momentum in March, recording a notable 9.5% month-on-month increase. Notably, cardiology and anti-infectives remained the top two therapy areas, reaffirming the buoyancy of the healthcare sector.

For feedback and suggestions, write to us at [e-mail]